These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36598389)

  • 21. Immunopathogenesis of thyroid eye disease: emerging paradigms.
    Naik VM; Naik MN; Goldberg RA; Smith TJ; Douglas RS
    Surv Ophthalmol; 2010; 55(3):215-26. PubMed ID: 20385333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating Thyroid Associated Ophthalmopathy in Pediatric Patients.
    Dong T; Fu Z; Wang X
    Front Endocrinol (Lausanne); 2022; 13():900204. PubMed ID: 35837312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
    Kumar S; Coenen M; Iyer S; Bahn RS
    Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
    Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
    J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.
    Cui X; Wang F; Liu C
    Front Immunol; 2023; 14():1062045. PubMed ID: 36742308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin, insulin-like growth factor-1, insulin receptor, and insulin-like growth factor-1 receptor expression in the chick eye and their regulation with imposed myopic or hyperopic defocus.
    Penha AM; Schaeffel F; Feldkaemper M
    Mol Vis; 2011; 17():1436-48. PubMed ID: 21655358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
    Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
    J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.
    Douglas RS
    Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
    Smith TJ
    Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
    Ding Y; Yang S; Gao H
    Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teprotumumab for Thyroid-Associated Ophthalmopathy.
    Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
    N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
    Smith TJ
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
    Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.
    Bid HK; Zhan J; Phelps DA; Kurmasheva RT; Houghton PJ
    Mol Cancer Ther; 2012 Mar; 11(3):649-59. PubMed ID: 22188815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enrichment of IGF-1R and PPARγ signalling pathways in orbital inflammatory diseases: steps toward understanding pathogenesis.
    Verma R; Choi D; Chen AJ; Harrington CA; Wilson DJ; Grossniklaus HE; Dailey RA; Ng J; Steele EA; Planck SR; Korn BS; Kikkawa D; Czyz CN; Foster JA; Kazim M; Harris GJ; Edward DP; Al-Hussain H; Maktabi AMY; Alabiad C; Garcia A; Rosenbaum JT
    Br J Ophthalmol; 2022 Jul; 106(7):1012-1017. PubMed ID: 33637620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.